NurExone Biologic Inc.
NRX.V
TSX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -6.16% | -32.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.94% | -19.54% | |||
| Operating Income | 8.94% | 19.54% | |||
| Income Before Tax | 4.78% | 20.64% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 4.78% | 20.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.78% | 20.64% | |||
| EBIT | 8.94% | 19.54% | |||
| EBITDA | 7.61% | 20.28% | |||
| EPS Basic | 15.34% | 22.22% | |||
| Normalized Basic EPS | 15.25% | 22.37% | |||
| EPS Diluted | 15.34% | 22.22% | |||
| Normalized Diluted EPS | 15.25% | 22.37% | |||
| Average Basic Shares Outstanding | 12.50% | 2.05% | |||
| Average Diluted Shares Outstanding | 12.50% | 2.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||